Key Stats for HCA Healthcare Stock
- Past-Week Performance: -2.9%
- 52-Week Range: $314.4 to $556.5
- Current Price: $493.9
What Happened?
HCA Healthcare (HCA), the largest for-profit hospital operator in the U.S., delivered its 19th consecutive quarter of volume growth in Q4 2025 while posting full-year net income of $6.78 billion, up 17.8%, even as the stock sits 11.3% below its 52-week high of $556.52.
CEO Samuel Hazen and CFO Michael Marks reported on Q4 2025 earnings call that full-year adjusted EBITDA grew 12.1%, margins expanded 90 basis points to 20.6%, and operating cash flow surged 20% to $12.6 billion, funding a record $10 billion share repurchase and a dividend raise from $0.72 to $0.78 per quarter.
HCA’s outpatient network, now roughly 2,700 facilities that funnel patients from urgent care and freestanding ERs into its hospitals, drove outpatient revenue growth above inpatient in Q4 2025, while the company added ~100 outpatient units during the year toward a target of 18-20 sites per hospital by decade-end.
Marks also stated at the Barclays Global Healthcare Conference on March 10 that “resiliency is not new for us,” adding that the $400 million cost savings program embedded in 2026 guidance “reflects those work streams where we had enough visibility on their implementation status that we could track and execute.”
HCA’s $7 billion capital pipeline, a new $10 billion buyback authorization, and AI tools already live across ~80 hospitals position the company to sustain its long-term 4%-6% EBITDA growth target through a policy environment that carries $600 million to $900 million in ACA exchange headwinds in 2026.
Wall Street’s Take on HCA Stock
The record $12.6 billion in 2025 operating cash flow, up 20% year-over-year, confirms that HCA’s margin durability is not a one-cycle event but a structural output of scale, shared services, and a resiliency program absorbing known policy headwinds before they hit the P&L.
Even with $600M to $900M in ACA exchange pressure baked into 2026 guidance, the TIKR model estimates revenue growing from $75.6B in 2025 to $78.7B in 2026, with normalized EPS rising from $28.21 to $30.33, supported by the $400M resiliency offset and 2%-3% volume growth assumption.
Thirteen of 24 covering analysts rate HCA a buy or outperform, with a mean price target of $543.05 implying 10.0% upside from the current $493.88, as Wall Street prices in successful resiliency execution and continued cash deployment into buybacks and network expansion.
The analyst price target range spans $425.00 on the low end to $635.00 on the high end, with the bear case hinging on exchange volume attrition exceeding the 15%-20% modeled decline and the bull case reflecting full Georgia and Florida supplemental payment approvals not yet in guidance.
What Does the Valuation Model Say?
The TIKR mid-case model prices HCA at $843.10 by December 2030, implying an 11.8% annual return, anchored by a 5.7% revenue CAGR, stable EBITDA margins near 20%, and 12.0% EPS CAGR even as the model assumes a -1.4% annual P/E contraction.
The market is treating ACA exchange headwinds as structural impairment; the $7.69B in 2025 free cash flow, a 10.2% FCF margin and a multi-year high, shows the underlying engine remains intact.
HCA’s $7 billion capital pipeline and AI tools already live in ~80 hospitals underpin the TIKR target of $843.10, with outpatient network expansion toward 20 sites per hospital driving the incremental volume growth embedded in the model.
Management’s new $10 billion buyback authorization, combined with the dividend raise to $0.78 per quarter declared in January, signals the board’s conviction that the stock is mispriced at current levels.
If ACA effectuation rates deteriorate beyond the modeled 15%-20% volume decline or Florida’s supplemental payment program fails to win CMS approval, the $400M resiliency offset loses its anchor and EBITDA guidance collapses toward the low end of the $15.55B-$16.45B range.
The Q1 2026 earnings call is the first hard test: watch same-facility exchange admissions and effectuation rate disclosures against the modeled 15%-20% volume decline to confirm whether the $400M resiliency program is tracking on schedule.
Should You Invest in HCA Healthcare, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up HCA stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track HCA Healthcare, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HCA stock on TIKR for Free →
